View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 2, 2019

MabSpace Biosciences merges with bioprocessing technology firm HJB

Hong Kong-based biotech company MabSpace Biosciences has signed a definitive agreement to merge with bioprocessing technologies provider HJB to form a biotherapeutics firm, which will be called Transcenta.

Hong Kong-based biotech company MabSpace Biosciences has signed a definitive agreement to merge with bioprocessing technologies provider HJB to form a biotherapeutics firm, which will be called Transcenta.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

The new entity will have research, development, regulatory and biologics manufacturing capabilities.

MabSpace primarily works on discovery, clinical research and commercial development of new biologic medicines, with focus on antibody-based therapeutics.

The company’s pipeline consists of more than ten antibody programmes across oncology, ophthalmology and nephrology areas. The products are based on its Immune Tolerance Breaking Technology antibody generation platform.

HJB designs and applies bioprocessing technologies to drive biologics R&D and manufacturing. The firm has operations in China and the US, including a 140,000ft² manufacturing facility.

The firm obtained rights for a variety of next-generation immunotherapy antibody programmes via in-licensing.

Transcenta is expected to leverage the capabilities of both MabSpace and HJB for the discovery, development and manufacturing of biologics-based drugs. It will have more than ten innovative pipeline molecules.

The combined entity is set to have operations in China and the US at Discovery and Translational Research Center, Suzhou; Process and Product Development Center and Manufacturing Facility, Hangzhou; and Clinical Development Centers in Shanghai, Beijing and Boston.

“With the merger of HJB and MabSpace, we can achieve a critical mass, significantly accelerate the development and commercialisation of our innovative pipeline.”

Transcenta will work towards reducing the timeline from target to BLA, and support the development and commercialisation of both in-house and strategic partner’s pipeline molecules.

Transcenta co-founder and CEO Xueming Qian said: “With the merger of HJB and MabSpace, we can achieve a critical mass, significantly accelerate the development and commercialisation of our innovative pipeline and establish Transcenta as a truly fully integrated biotherapeutics-focused global biotech company.

“This not only enables shorter development timelines, but also provides high-quality biotherapeutics at a much lower cost to ensure affordability and sustained profitability.”

HJB and MabSpace have so far collectively raised nearly $160m from multiple investors, including Lilly Asia Ventures, Sequoia China, Temasek, Taikang, ARCH Venture Partners and Teng Yue Partners.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology